Merck (MRK) Invested Capital (2009 - 2026)

Merck (MRK) has 18 years of Invested Capital data on file, last reported at $48.3 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at $48.3 billion, down 2.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.3 billion (down 2.89% YoY), and the FY2025 annual result was $55.3 billion, up 12.71% from the prior year.
• Invested Capital fell to $48.3 billion in Q1 2026 per MRK's latest filing, from $55.3 billion in the prior quarter.
• Over five years, Invested Capital peaked at $55.3 billion in Q4 2025 and troughed at $39.0 billion in Q4 2023.
• A 5-year average of $47.0 billion and a median of $47.7 billion in 2024 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2023: Invested Capital grew 29.05% in 2022, then slipped 18.74% in 2023.
• A 5-year view of Invested Capital shows it stood at $48.0 billion in 2022, then fell by 18.74% to $39.0 billion in 2023, then increased by 25.67% to $49.0 billion in 2024, then gained by 12.71% to $55.3 billion in 2025, then slipped by 12.54% to $48.3 billion in 2026.
• Business Quant data shows MRK's Invested Capital at $48.3 billion in Q1 2026, $55.3 billion in Q4 2025, and $53.3 billion in Q3 2025.